ClinicalTrials.gg
CompletedNCT04592809TASKUpdated Oct 15, 2026Results posted

Ketamine Versus Midazolam for Recurrence of Suicidality in Adolescents

A Phase 3 interventional study of Ketamine Hydrochloride and Midazolam Hydrochloride in Suicide, Attempted, Suicide and Depression and Suicide Threat, sponsored by University of Texas Southwestern Medical Center. Completed at 1 site in United States. Open to participants aged 13 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by University of Texas Southwestern Medical Center · Phase 3, Interventional, and Treatment

How we know

Updated Oct 15, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
13 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 149 studies in Suicide, Attempted with a site in United States — 53 open to participants now, 58 under way, 1 of them phase 3. Suicide, Attempted · United States.

Enrollment
100th of 140
50 · median 117
Started
2022
with 16 others
Phase 3
3 of 149
1 open now
Registered
66th of 149
by date
Lead sponsor
8 of 149
University of Texas Southwestern Medical Center

Among the 149 studies in Suicide, Attempted with a site in United States, this one is the 100th largest by enrollment of the 140 interventional ones that give a count, is one of 17 that started in 2022, is one of 3 in phase 3, and was the 66th registered.

Suicide, Attempted

281 studies on the registry are indexed under Suicide, Attempted; 90 are open to participants now.

Browse Suicide, Attempted studies →

Open to participants now

53 of the 149 studies in Suicide, Attempted with a site in United States are open now. Recruiting first, the newest first:

48 more — sign in →

All 53 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 67 Suicide, Attempted studies recruiting now, 34 (51%) set no upper age limit and 32 (48%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.

This study: 13 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 149 studies in Suicide, Attempted with a site in United States, or all of them as a file.
02

Study summary

This project aims to examine the signal of efficacy of ketamine, a rapidly acting medication shown to decrease suicidality in adults in as short as hours or days, as opposed to weeks.

The study design is a double-blind, randomized, active-control trial of adolescents (ages 13-18 years) with recent suicidal behaviors (suicide attempt or increased suicidal ideation). All participants must be receiving standard of care treatment which may range broadly from both outpatient and inpatient programs which include clinically indicated psychosocial and/or psychopharmacological treatments. Ketamine/midazolam treatment will occur twice weekly during the first two weeks of the study, followed by weekly assessments through week 12.

Read the detailed description

Adolescent patients (ages 13-18) who have recent suicidality (defined as suicide attempt or urgent evaluation for a suicidal ideation or behavior), and who are receiving standard of care treatment (e.g., psychosocial and/or psychopharmacological treatment) will be recruited for participation in the study. Upon informed consent/assent, screening data will be collected regarding mood symptoms, suicidal ideation and behavior, associated comorbidities, and treatment history. Youth participants will be randomized to receive infusions of either ketamine or midazolam, which will be provided twice weekly for two weeks. Participants will then have follow-up assessments visits through week 12 to continue to monitoring outcome measures.

Participants may be recruited directly from their standard care outpatient provider, SPARC Intensive Outpatient Program (IOP) located at Children's Health Medical Center, from the Children's Health Emergency Department (ED) or inpatient psychiatric unit located at the Dallas campus. Participants may also be recruited into the study even if they are seen in the in emergency departments or inpatient hospitalization outside of University of Texas (UT) Southwestern and Children's Health Medical Center. Recruitment and consent procedures may begin during ED or inpatient hospitalization; however, as the study is an outpatient study, study procedures will not begin until the participant is discharged from the ED or inpatient hospital.

Recruitment efforts will target medically healthy male and female youths with recent suicide events who are either seeking care at an emergency room, admitted to an inpatient unit, enrolled in an IOP, or receiving adequate outpatient care with either psychopharmacological or psychosocial treatment following a suicide event.

Enrollment of 114 subjects is expected to take place over a period of approximately 36 months. Enrolled participants will be involved in the study for approximately 14 weeks. Visits include a Screening Visit, 4 Study Intervention Visits, and 11 Follow-Up Visits (combination of in-person and remote visits). Multiple streams of outcome measures will be utilized for this protocol, including self-report measures, research assessor-completed measures, clinic level measures, and behavioral measures.

Aim 1. Evaluate reduction in repeat suicidal events with ketamine.

Aim 2. Evaluate reduction in implicit suicidal cognition with ketamine.

Aim 3. Evaluate reduction in depressive symptoms and suicidality with ketamine.

03

Conditions studied

  • Suicide, Attempted
  • Suicide and Depression
  • Suicide Threat

Keywords

  • depression
  • adolescent
  • suicidal ideation
  • suicide attempt
  • teen
  • child
  • intensive outpatient
  • inpatient hospitalization
  • depression treatment
  • suicide treatment
04

Who can participate

Ages eligible
13 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Study participants must:

  1. Be adolescents (aged 13-18 years);
  2. Have had a recent suicidal event (suicide attempt or significant suicidal ideation with a plan or intent warranting emergency evaluation or inpatient hospitalization within the past 90 days);
  3. Receiving standard of care treatment that includes clinically indicated psychosocial and/or psychopharmacological treatment;
  4. Have a current primary diagnosis of a depressive disorder based on the MINI-KID (other psychiatric disorders are acceptable, but must not be primary);
  5. Participants must be able to complete assessments in English. However, the parent(s) or legal guardians of minors may either speak English or Spanish
  6. Use effective method of during and for 90 days following the end of treatment for female and male participants. Recommended methods of birth control are namely, consistent use of an approved hormonal birth control (pill/patches, rings), an intrauterine device (IUD), contraceptive injection, double barrier methods, sexual abstinence, or sterilization;

Exclusion criteria

Exclusion Criteria

Study participants must not:

  1. Have a psychotic disorder, such as lifetime schizophrenia, or a pervasive or intellectual developmental disorder requiring substantial or very substantial support;
  2. Have current mania, hypomania, mixed episode, or obsessive-compulsive disorder;
  3. Have a primary diagnosis other than a depressive disorder;
  4. Have moderate to severe alcohol or substance use disorder within the past six months (based on MINI-KID); If there is a positive urine drug screen at screening, the urine drug screen will be repeated at each infusion visit. Positive urine drug screen will be reviewed by study physician and infusion will proceed as long as no safety risk was identified;
  5. If female, be pregnant, lactating, or nursing; Women of must have a negative urine pregnancy test prior to all infusions;
  6. Have unstable medical conditions (stable for less than 3 months) or with laboratory values or an (ECG) that would pose significant risk;
  7. Be at serious suicidal risk that cannot be managed in the outpatient setting;
  8. Have prior treatment for depression with or to ketamine, esketamine, or, midazolam;
  9. Treatment with medications that may alter pharmacokinetics of ketamine, including moderate-to-strong inhibitors or inducers of and CYP2B6, is exclusionary. Regarding pharmacodynamic interactions, medications that may increase heart rate or blood pressure such as the ADHD stimulant medications will be permitted with last dose at least 24 hours prior to infusion. All concomitant medications will be evaluated by the study physician to determine if the type and dose of concomitant medication requires discontinuation and will be excluded if the concomitant medication could substantially increase the risk of study infusion. A complete list of medications that are Not Allowed is available in Appendix D of the protocol. The study team will not ask the participant to discontinue any treatment (except for not taking ADHD medications for 24 hours before study treatment) just for the sake of taking part in this study;
  10. Weigh >120 kilograms at baseline. If participants are enrolled but exceed 120 kilograms at any time during the treatment period, they will be removed from the treatment portion of the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
50 participants (actual)

Study arms

  • Active comparator
    Ketamine

    0.5 mg/kg intravenous ketamine will be administered 4 times in a 2 week period. Ketamine will be dissolved in 0.9% sodium chloride in a total volume of 100ml and administered with a syringe infusion pump at a constant rate.

    Drug: Ketamine Hydrochloride · Drug: Midazolam Hydrochloride

  • Active comparator
    Midazolam

    0.02 mg/kg midazolam will be administered 4 times in a 2 week period. Midazolam will be dissolved in 0.9% sodium chloride in a total volume of 100ml and administered with a syringe infusion pump at a constant rate.

    Drug: Ketamine Hydrochloride · Drug: Midazolam Hydrochloride

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Days to First Suicidal Event

    The primary outcome is number of days from the beginning of the study until the first suicidal event. A suicidal event is defined as a suicide attempt, or emergency department visit or inpatient hospitalization due to suicidality. Concise Health Risk Tracking Clinician-Rated Behavior Module (CHRT-C) will be used to identify suicidal events. The CHRT-C consists of nine clinician-rated yes/no items about specific behaviors (i.e., suicidal ideation, suicidal attempt, preparatory acts, non-suicidal self-injury (NSSI), other injuries, etc.). At the initial administration, this instrument captures lifetime information; at subsequent administrations, it will capture information since the last visit. Mean (Standard Error) days to event was estimated by Kaplan-Meier survival curves.

    Time frame: 12 weeks

  2. Number of Days to First Suicidal Event (by Sex)

    The primary outcome is number of days from the beginning of the study until the first suicidal event. A suicidal event is defined as a suicide attempt, or emergency department visit or inpatient hospitalization due to suicidality. Concise Health Risk Tracking Clinician-Rated Behavior Module (CHRT-C) will be used to identify suicidal events. The CHRT-C consists of nine clinician-rated yes/no items about specific behaviors (i.e., suicidal ideation, suicidal attempt, preparatory acts, non-suicidal self-injury (NSSI), other injuries, etc.). At the initial administration, this instrument captures lifetime information; at subsequent administrations, it will capture information since the last visit. Mean (Standard Error) days to event was estimated by Kaplan-Meier survival curves.

    Time frame: 12 weeks

  3. Number of Days to First Suicidal Event (by Ethnicity)

    The primary outcome is number of days from the beginning of the study until the first suicidal event. A suicidal event is defined as a suicide attempt, or emergency department visit or inpatient hospitalization due to suicidality. Concise Health Risk Tracking Clinician-Rated Behavior Module (CHRT-C) will be used to identify suicidal events. The CHRT-C consists of nine clinician-rated yes/no items about specific behaviors (i.e., suicidal ideation, suicidal attempt, preparatory acts, non-suicidal self-injury (NSSI), other injuries, etc.). At the initial administration, this instrument captures lifetime information; at subsequent administrations, it will capture information since the last visit. Mean (Standard Error) days to event was estimated by Kaplan-Meier survival curves.

    Time frame: 12 weeks

  4. Number of Days to First Suicidal Event (by Race)

    The primary outcome is number of days from the beginning of the study until the first suicidal event. A suicidal event is defined as a suicide attempt, or emergency department visit or inpatient hospitalization due to suicidality. Concise Health Risk Tracking Clinician-Rated Behavior Module (CHRT-C) will be used to identify suicidal events. The CHRT-C consists of nine clinician-rated yes/no items about specific behaviors (i.e., suicidal ideation, suicidal attempt, preparatory acts, non-suicidal self-injury (NSSI), other injuries, etc.). At the initial administration, this instrument captures lifetime information; at subsequent administrations, it will capture information since the last visit. Mean (Standard Error) days to event was estimated by Kaplan-Meier survival curves.

    Time frame: 12 weeks

Secondary outcomes

  1. Death/Suicide Implicit Association Test (IAT) Score

    The Death/Suicide Implicit Association Test (IAT) is computerized reaction-time test designed to measure implicit associations between the self and death. Participants categorize stimuli representing 1) self versus non-self, and 2) death versus life concepts. Based on response latencies across task conditions, a score is computed. Positive scores represent faster response time on association between death and self, while negative scores represent stronger associations between life and self. Thus, higher scores indicate a worse outcome. The scale is based on reaction times so there is not a fixed range.

    Time frame: 2 weeks

  2. Concise Health Risk Tracking Self-Report (CHRT-SR) Score

    Concise Health Risk Tracking Self-Report (CHRT-SR) consists of 14 questions with responses ranging from 0 (strongly disagree) to 4 (strongly agree). A total score is calculated by the sum of all 14 responses, with a total ranging from 0 to 56. A higher score indicates a greater risk for suicide.

    Time frame: 2 weeks

  3. Percentage of Participants With Suicidal Events/Behaviors as Measured by CHRT-C a Self Report Measure

    Concise Health Risk Tracking Clinician-Rated Behavior Module (CHRT-C). consists of nine clinician-rated yes/no items about specific behaviors (i.e., suicidal ideation, suicidal attempt, preparatory acts, non-suicidal self-injury (NSSI), other injuries, etc.). At the initial administration, this instrument captures lifetime information; at subsequent administrations, it will capture information since the last visit. a yes on any of the 9 questions indicates presence of suicidal event/behaviors (ideation, attempt, preparatory acts, non suicidal self injury, other injury).

    Time frame: 2 week

  4. Inventory of Depressive Symptomatology (IDS) Self Report Score

    The Inventory of Depressive Symptomatology (IDS) Self Report is a depressive symptom severity measure that rates all nine criterion symptoms of MDD. The self-report (IDS-SR) consists of 30 questions with a total score of 0 to 84. A higher score indicates a higher level of depressive symptom severity. The self report (IDS-SR) will be completed at each visit.

    Time frame: 2 weeks

07

Results

Posted Oct 15, 2026

Participant flow

Participant flow — Overall Study
MilestoneKetamineMidazolam
Started2822
Completed2621
Not completed21

Outcome measures

PrimaryNumber of Days to First Suicidal Event

The primary outcome is number of days from the beginning of the study until the first suicidal event. A suicidal event is defined as a suicide attempt, or emergency department visit or inpatient hospitalization due to suicidality. Concise Health Risk Tracking Clinician-Rated Behavior Module (CHRT-C) will be used to identify suicidal events. The CHRT-C consists of nine clinician-rated yes/no items about specific behaviors (i.e., suicidal ideation, suicidal attempt, preparatory acts, non-suicidal self-injury (NSSI), other injuries, etc.). At the initial administration, this instrument captures lifetime information; at subsequent administrations, it will capture information since the last visit. Mean (Standard Error) days to event was estimated by Kaplan-Meier survival curves.

Time frame:
12 weeks
Reported as:
Mean · Days to event
Number of Days to First Suicidal Event
Days to eventKetamineMidazolam
Number of Days to First Suicidal Event75.86 ± 3.635.59 ± 1.6
SecondaryDeath/Suicide Implicit Association Test (IAT) Score

The Death/Suicide Implicit Association Test (IAT) is computerized reaction-time test designed to measure implicit associations between the self and death. Participants categorize stimuli representing 1) self versus non-self, and 2) death versus life concepts. Based on response latencies across task conditions, a score is computed. Positive scores represent faster response time on association between death and self, while negative scores represent stronger associations between life and self. Thus, higher scores indicate a worse outcome. The scale is based on reaction times so there is not a fixed range.

Time frame:
2 weeks
Reported as:
Mean · score on a scale
Death/Suicide Implicit Association Test (IAT) Score
score on a scaleKetamineMidazolam
Death/Suicide Implicit Association Test (IAT) Score.212 ± .06.80 ± .08
SecondaryConcise Health Risk Tracking Self-Report (CHRT-SR) Score

Concise Health Risk Tracking Self-Report (CHRT-SR) consists of 14 questions with responses ranging from 0 (strongly disagree) to 4 (strongly agree). A total score is calculated by the sum of all 14 responses, with a total ranging from 0 to 56. A higher score indicates a greater risk for suicide.

Time frame:
2 weeks
Reported as:
Mean · score on a scale
Concise Health Risk Tracking Self-Report (CHRT-SR) Score
score on a scaleKetamineMidazolam
Concise Health Risk Tracking Self-Report (CHRT-SR) Score19.26 ± 2.118.42 ± 2.3
SecondaryPercentage of Participants With Suicidal Events/Behaviors as Measured by CHRT-C a Self Report Measure

Concise Health Risk Tracking Clinician-Rated Behavior Module (CHRT-C). consists of nine clinician-rated yes/no items about specific behaviors (i.e., suicidal ideation, suicidal attempt, preparatory acts, non-suicidal self-injury (NSSI), other injuries, etc.). At the initial administration, this instrument captures lifetime information; at subsequent administrations, it will capture information since the last visit. a yes on any of the 9 questions indicates presence of suicidal event/behaviors (ideation, attempt, preparatory acts, non suicidal self injury, other injury).

Time frame:
2 week
Reported as:
Number · percentage of subjects
Percentage of Participants With Suicidal Events/Behaviors as Measured by CHRT-C a Self Report Measure
percentage of subjectsKetamineMidazolam
Percentage of Participants With Suicidal Events/Behaviors as Measured by CHRT-C a Self Report Measure89.3068.20
SecondaryInventory of Depressive Symptomatology (IDS) Self Report Score

The Inventory of Depressive Symptomatology (IDS) Self Report is a depressive symptom severity measure that rates all nine criterion symptoms of MDD. The self-report (IDS-SR) consists of 30 questions with a total score of 0 to 84. A higher score indicates a higher level of depressive symptom severity. The self report (IDS-SR) will be completed at each visit.

Time frame:
2 weeks
Reported as:
Mean · score on a scale
Inventory of Depressive Symptomatology (IDS) Self Report Score
score on a scaleKetamineMidazolam
Inventory of Depressive Symptomatology (IDS) Self Report Score18.09 ± 2.216.44 ± 2.4
PrimaryNumber of Days to First Suicidal Event (by Sex)

The primary outcome is number of days from the beginning of the study until the first suicidal event. A suicidal event is defined as a suicide attempt, or emergency department visit or inpatient hospitalization due to suicidality. Concise Health Risk Tracking Clinician-Rated Behavior Module (CHRT-C) will be used to identify suicidal events. The CHRT-C consists of nine clinician-rated yes/no items about specific behaviors (i.e., suicidal ideation, suicidal attempt, preparatory acts, non-suicidal self-injury (NSSI), other injuries, etc.). At the initial administration, this instrument captures lifetime information; at subsequent administrations, it will capture information since the last visit. Mean (Standard Error) days to event was estimated by Kaplan-Meier survival curves.

Time frame:
12 weeks
Reported as:
Mean · Days to event
Number of Days to First Suicidal Event (by Sex)
Days to eventKetamineMidazolam
MaleNA ± NANA ± NA
Female74.15 ± 4.539.36 ± 1.8
PrimaryNumber of Days to First Suicidal Event (by Ethnicity)

The primary outcome is number of days from the beginning of the study until the first suicidal event. A suicidal event is defined as a suicide attempt, or emergency department visit or inpatient hospitalization due to suicidality. Concise Health Risk Tracking Clinician-Rated Behavior Module (CHRT-C) will be used to identify suicidal events. The CHRT-C consists of nine clinician-rated yes/no items about specific behaviors (i.e., suicidal ideation, suicidal attempt, preparatory acts, non-suicidal self-injury (NSSI), other injuries, etc.). At the initial administration, this instrument captures lifetime information; at subsequent administrations, it will capture information since the last visit. Mean (Standard Error) days to event was estimated by Kaplan-Meier survival curves.

Time frame:
12 weeks
Reported as:
Mean · Days to event
Number of Days to First Suicidal Event (by Ethnicity)
Days to eventKetamineMidazolam
Hispanic or Latino50 ± NA40.75 ± .3
Not Hispanic or Latino75.18 ± 4.812 ± NA
PrimaryNumber of Days to First Suicidal Event (by Race)

The primary outcome is number of days from the beginning of the study until the first suicidal event. A suicidal event is defined as a suicide attempt, or emergency department visit or inpatient hospitalization due to suicidality. Concise Health Risk Tracking Clinician-Rated Behavior Module (CHRT-C) will be used to identify suicidal events. The CHRT-C consists of nine clinician-rated yes/no items about specific behaviors (i.e., suicidal ideation, suicidal attempt, preparatory acts, non-suicidal self-injury (NSSI), other injuries, etc.). At the initial administration, this instrument captures lifetime information; at subsequent administrations, it will capture information since the last visit. Mean (Standard Error) days to event was estimated by Kaplan-Meier survival curves.

Time frame:
12 weeks
Reported as:
Mean · Days to event
Number of Days to First Suicidal Event (by Race)
Days to eventKetamineMidazolam
American Indian or Alaska Native American Indian or Alaska NativeNA ± NANA ± NA
AsianNA ± NA—
Native Hawaiian or Other Pacific IslanderNA ± NA—
Black or African American25 ± NANA ± NA
White73.76 ± 4.739.18 ± 2.0
Unknown or not reportedNA ± NANA ± NA

Adverse events

Collected over Adverse Events were assessed for up to 14 weeks (from the time of informed consent until participant's exit from the study).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ketamine0/28 (0%)5/28 (17.9%)28/28 (100%)
Midazolam0/22 (0%)7/22 (31.8%)22/22 (100%)
Most frequent serious events
Most frequent serious events
EventKetamineMidazolam
Suicide AttemptPsychiatric disorders5/285/22
Active Suicidal IdeationPsychiatric disorders0/284/22
Suicidal IdeationPsychiatric disorders1/281/22
Sexually inappropriate behaviorPsychiatric disorders0/281/22
Self injurious behavior without suicidal intentPsychiatric disorders0/281/22
Eating DisorderPsychiatric disorders1/280/22
Most frequent other events
Showing 10 of 51
Most frequent other events
EventKetamineMidazolam
Perceptual disturbancePsychiatric disorders26/285/22
Time perception alteredPsychiatric disorders24/287/22
DepersonalizationPsychiatric disorders23/282/22
TirednessGeneral disorders17/2814/22
DizzinessNervous system disorders16/283/22
Numbness mouthNervous system disorders16/281/22
Blurry visionNervous system disorders15/282/22
NauseuaGastrointestinal disorders11/287/22
SedationNervous system disorders10/281/22
HeadacheNervous system disorders8/287/22

Baseline characteristics

Age, Customized
Age, Customized(Participants)KetamineMidazolamTotal
13-14 years9817
15-17 years181230
18 years123
Sex: Female, Male
Sex: Female, Male(Participants)KetamineMidazolamTotal
Female221941
Male639
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)KetamineMidazolamTotal
Hispanic or Latino8816
Not Hispanic or Latino201434
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)KetamineMidazolamTotal
American Indian or Alaska Native112
Asian202
Native Hawaiian or Other Pacific Islander101
Black or African American134
White181432
More than one race336
Unknown or Not Reported213
CHRT-SR
CHRT-SR(units on a scale)KetamineMidazolamTotal
Mean33.04 ± 11.427.00 ± 12.630.38 ± 12.2
IDS-SR
IDS-SR(units on a scale)KetamineMidazolamTotal
Mean34.46 ± 11.632.50 ± 12.233.60 ± 11.8
08

Study locations

1 site
  • UT Southwestern Medical Center
    Dallas, Texas 75235, United States
09

References and documents

Publications

  • Trivedi MH, Chin Fatt CR, Ayvaci ER, Mayes TL, Jha MK, Pak TK, Rebstock S, Spain T, Walsh D, Kimatian S, Monastirsky M, Vasu S, Carmody TJ, Minhajuddin A, Kennard BD, Emslie GJ. Randomized controlled trial of acute ketamine versus midazolam for recurrence of suicidality in adolescents (TASK): Rationale, design, and baseline characteristics. Contemp Clin Trials. 2026 Oct 8;170:108498. doi: 10.1016/j.cct.2026.108498. Online ahead of print. PubMed 42849709 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2022 to primary completion in Jul 2025, 32 months.

Results were first posted in Oct 2026, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2020
First posted
Oct 19, 2020
StartActual
Oct 3, 2022
Primary completionActual
Jul 1, 2025
CompletionActual
Aug 31, 2025
Results first posted
Oct 15, 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 15, 2026
Primary outcomes
4 added, 1 removed
What changed in the outcomes
  • AddedNumber of Days to First Suicidal EventTime frame: 12 weeks
  • AddedNumber of Days to First Suicidal Event (by Sex)Time frame: 12 weeks
  • AddedNumber of Days to First Suicidal Event (by Ethnicity)Time frame: 12 weeks
  • AddedNumber of Days to First Suicidal Event (by Race)Time frame: 12 weeks
  • RemovedThe primary outcome for the study is "suicidal events". Suicidal event is defined as a suicide attempt, or emergency department visit or inpatient hospitalization due to suicidality.Time frame: 12 weeks
Oct 15, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42849709 ↗
Oct 15, 2026
Secondary outcomes
4 edited
What changed in the outcomes
  • EditedDeath/Suicide Implicit Association Test (IAT) ScoreTime frame: 2 weeks
  • EditedDepression symptomsPercentage of Participants With Suicidal Events/Behaviors as measuredMeasured by CHRT-SRC a self report measureSelf Report MeasureTime frame: 2 weeks → 2 week
  • EditedDepression symptoms as measured by the Inventory of Depressive Symptomatology (IDS), self-report measure Self Report ScoreTime frame: 2 weeks
  • ChangedBefore Number of participants with suicidal events/behaviors as measured by CHRT-C a self report measureNow Concise Health Risk Tracking Self-Report (CHRT-SR) ScoreTime frame: 2 week → 2 weeks
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Results posted
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42849709 ↗
    Primary outcomes 4 added, 1 removed
    What changed in the outcomes
    • AddedNumber of Days to First Suicidal EventTime frame: 12 weeks
    • AddedNumber of Days to First Suicidal Event (by Sex)Time frame: 12 weeks
    • AddedNumber of Days to First Suicidal Event (by Ethnicity)Time frame: 12 weeks
    • AddedNumber of Days to First Suicidal Event (by Race)Time frame: 12 weeks
    • RemovedThe primary outcome for the study is "suicidal events". Suicidal event is defined as a suicide attempt, or emergency department visit or inpatient hospitalization due to suicidality.Time frame: 12 weeks
    Secondary outcomes 4 edited
    What changed in the outcomes
    • EditedDeath/Suicide Implicit Association Test (IAT) ScoreTime frame: 2 weeks
    • EditedDepression symptomsPercentage of Participants With Suicidal Events/Behaviors as measuredMeasured by CHRT-SRC a self report measureSelf Report MeasureTime frame: 2 weeks → 2 week
    • EditedDepression symptoms as measured by the Inventory of Depressive Symptomatology (IDS), self-report measure Self Report ScoreTime frame: 2 weeks
    • ChangedBefore Number of participants with suicidal events/behaviors as measured by CHRT-C a self report measureNow Concise Health Risk Tracking Self-Report (CHRT-SR) ScoreTime frame: 2 week → 2 weeks
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04592809
Responsible party
Madhukar H. Trivedi, MD (Professor, University of Texas Southwestern Medical Center) — Principal investigator
First posted
Oct 19, 2020
Start date
Oct 3, 2022
Primary completion
Jul 1, 2025
Completion
Aug 31, 2025
Results posted
Oct 15, 2026
Last update
Oct 15, 2026

Study contacts

Madhukar Trivedi, MD
principal investigator · University of Texas Southwestern Medical Center

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ketamine · Midazolam

Start the discussion